Cost-effectiveness of 13-valent pneumococcal conjugate vaccine: Germany, Greece, and The Netherlands
- 7 November 2011
- journal article
- research article
- Published by Elsevier in Journal of Infection
- Vol. 64 (1), 54-67
- https://doi.org/10.1016/j.jinf.2011.10.015
Abstract
No abstract availableKeywords
This publication has 51 references indexed in Scilit:
- Herd immunity and serotype replacement 4 years after seven-valent pneumococcal conjugate vaccination in England and Wales: an observational cohort studyThe Lancet Infectious Diseases, 2011
- Impact of the seven-valent pneumococcal conjugate vaccination (PCV7) programme on childhood hospital admissions for bacterial pneumonia and empyema in England: national time-trends study, 1997-2008Thorax, 2010
- Pharmacoeconomic evaluation of 10- and 13-valent pneumococcal conjugate vaccinesVaccine, 2010
- Invasive pneumococcal disease in the Netherlands: Syndromes, outcome and potential vaccine benefitsVaccine, 2009
- Cost effectiveness analysis of heptavalent pneumococcal conjugate vaccine in Germany considering herd immunity effectsThe European Journal of Health Economics, 2008
- Population Snapshot of EmergentStreptococcus pneumoniaeSerotype 19A in the United States, 2005The Journal of Infectious Diseases, 2008
- Meningitis registry of hospitalized cases in children: epidemiological patterns of acute bacterial meningitis throughout a 32-year periodBMC Infectious Diseases, 2007
- Cost-effectiveness of heptavalent conjugate pneumococcal vaccine (Prevenar) in Germany: considering a high-risk population and herd immunity effectsThe European Journal of Health Economics, 2007
- Effectiveness of seven-valent pneumococcal conjugate vaccine against invasive pneumococcal disease: a matched case-control studyThe Lancet, 2006
- Efficacy of a Pneumococcal Conjugate Vaccine against Acute Otitis MediaNew England Journal of Medicine, 2001